Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia

OBJECTIVES: Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting cell w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornely, Oliver A, Ostermann, Helmut, Koehler, Philipp, Teschner, Daniel, Limburg, Endrik, Kramer, William G, Barbat, Sara H, Tawadrous, Margaret, Hodges, Michael R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631825/
https://www.ncbi.nlm.nih.gov/pubmed/37681450
http://dx.doi.org/10.1093/jac/dkad269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631825/
https://www.ncbi.nlm.nih.gov/pubmed/37681450
http://dx.doi.org/10.1093/jac/dkad269

Ejemplares similares